
September 2007

Volume 12 · Numbers 17/18 pp. 683–788





Cover Story

In this month's Keynote Review, Peter Sartipy and co-authors discuss how human embryonic stem cells technologies can advance drug discovery. It is already known that the study of embryonic stem cells will be of significant benefit for the understanding of cell development and differentiation. Moreover, due to their differentiation potential, stem cells are expected be of use in regenerative medicine. A new development is that novel in vitro models based on undifferentiated or selectively differentiated human stem cells will be instrumental for increasing R&D productivity in the pharmaceutical industry. Cover image by David Scharf/ Science Photo Library.

REVIEWS

KEYNOTE

688 The application of human embryonic stem cell technologies to drug discovery

Peter Sartipy, Petter Björquist, Raimund Strehl and Johan Hyllner

GENE TO SCREEN

700 The ongoing evolution of proteomics in malignancy Amit S. Dhamoon, Elise C. Kohn and Nilofer S. Azad

709 Human protein–protein interaction networks and the value for drug discovery

Heinz Ruffner, Andreas Bauer and Tewis Bouwmeester

717 Dissecting kinase signaling pathways

Scott N. Boyle and Anthony J. Koleske

INFORMATICS

725 The role of quantum mechanics in structure-based drug design

Kaushik Raha, Martin B. Peters, Bing Wang, Ning Yu, Andrew M. Wollacott, Lance M. Westerhoff and Kenneth M. Merz Ir

732 Rapid retrieval of protein structures from databases

Zeyar Aung and Kian-Lee Tan

POST SCREEN

740 Modulation of sterol regulatory element binding proteins (SREBPs) as potential treatments for non-alcoholic fatty liver disease (NAFLD) Mohamed H. Ahmed and Christopher D. Byrne

748 PET tracers for 5-HT_{1A} receptors and uses thereof J.S. Dileep Kumar and J. John Mann

757 Designing drugs for the treatment of female sexual dysfunction Alan D. Brown, Julian Blagg and David S. Reynolds

767 Progress in the discovery and development of glutamate carboxypeptidase II inhibitors

Takashi Tsukamoto, Krystyna M. Wozniak and Barbara S. Slusher

777 The significance of mitochondrial toxicity testing in drug development James A. Dykens and Yvonne Will